TURKISH JOURNAL of ONCOLOGY

Turk J Oncol 2025;40(3):242–251
doi: 10.5505/tjo.2025.4576

REVIEW

The Complex Interplay of Autophagy and Tumor Immunity: A Comprehensive Review of Therapeutic Approaches

Mohammadhossein KOUHPAEENEJAD,[1] Seyed Amirhossein SEYED ALI KHANI,[2] Mostafa ESLAMIMAHMOUDABADI,[2] Hassan NIKOUEINEJAD,[3] Nesa RASHIDI[4]

[1]Department of General Medicine, Baqiyatallah University of Medical Sciences Faculty of Medicine, Tehran-*Iran*
[2]Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran-*Iran*
[3]Department of Clinical Immunology and Allergy, Atieh Hospital, Tehran-*Iran*
[4]Department of Immunology, Baqiyatallah University of Medical Sciences Faculty of Medicine, Tehran-*Iran*

SUMMARY

Autophagy is a conserved cellular mechanism that removes cytoplasmic components, such as organelles and proteins, in response to numerous stressors. In cancer, autophagy plays a complex and context-dependent role, where it can either suppress or promote tumor growth, depending on the cancer type, stage, and the tumor microenvironment (TME). This review focuses on the involvement of autophagy in immune responses to tumors and potential therapeutic approaches, emphasizing the intricate interaction among autophagy, tumor cells, and the immune system to target autophagy in cancer treatment. We discuss how autophagy influences tumor immunity, including its impact on immune cell activation, antigen presentation, and immune evasion mechanisms. The review also provides insights into current strategies for targeting autophagy in cancer therapy, including the development of specific inhibitors and potential biomarkers for patient stratification. While autophagy-targeting approaches show promise in preclinical studies, challenges remain in translating these findings into clinical applications.

Keywords: Autophagy; checkpoint inhibitors; immunotherapy; tumor microenvironment.

INTRODUCTION

Autophagy is a biological mechanism where cells degrade and recycle cellular components to preserve cellular homeostasis. The formation of autophagosomes, which are double-membraned vesicles, characterizes this process. These autophagosomes encompass and engulf cytoplasmic components, thereby merging them with lysosomes to produce autolysosomes. Inside the autolysosomes, the cargo is degraded and recycled.[1] Autophagy contributes to multiple biological processes, e.g., cell proliferation, differentiation, and survival. When autophagy is improperly regulated, it can result in the development or progress of various disorders, including cancer.[2] Cancer is a perilous, complex, and multifactorial disease that arises from the uncontrollable proliferation and spread of aberrant cells. Tumor cells utilize various processes to evade the immune system, thereby facilitating their survival, proliferation, and metastasis. The role of autophagy in tumor immunity and therapy has fascinated researchers in recent years. It is now evident that autophagy prominently influences tumor cell survival, immune cell activity, and response to therapy.[3] This review discusses the involvement of autophagy in tumor immunity and its importance for cancer therapy. First, we provide a

Received: June 20, 2025
Revised: July 14, 2025
Accepted: August 07, 2025
Online: September 03, 2025

Accessible online at:
www.onkder.org

Dr. Nesa RASHIDI
Department of Immunology,
Baqiyatallah University of Medical Sciences Faculty of Medicine,
Tehran-Iran
E-mail: nesa.rashidi@gmail.com

comprehensive overview of the molecular processes involved in autophagy and the factors that regulate its function. Next, we consider the intricate relationship among autophagy, cancer cells, and the immune system, including the influence of autophagy on evading the immune response, inflammation associated with tumors, and the tumor microenvironment (TME). Eventually, we discuss possible therapeutic approaches for focusing on autophagy in cancer treatment, as well as the challenges and future opportunities in this field.

Activation and Regulation of Autophagy

Autophagy is one of the most precisely regulated processes within the cell, initiated by activation of ULK1 complex. This complex is made up of ULK1, Atg13, FIP200, and Atg101. The mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) strictly controls this complex. mTORC1 is one of the main regulators of cell metabolism and proliferation. It suppresses autophagy when nutrients are abundant.[4] Whenever the body receives different stress signals, such as lack of nutrients, low oxygen levels, or damaged organelles, mTORC1 becomes inactivated. This deactivation leads to the activation of the ULK1 complex, which then initiates the autophagy process.[5] The initiation of autophagosome membrane formation is facilitated by the class III phosphatidyl 3-kinase (PI3K) complex, including Vps34, Vps15, Beclin 1, and Atg14L. The formation of this complex structure begins with the production of phosphatidyl 3-phosphate (PI3P), which recruits PI3P-binding proteins to the autophagosome membrane, promoting its expansion.[6] Atg12-Atg5-Atg16L1 and LC3-II (the lipidated form of microtubule-associated protein 1 light chain 3, or MAP1LC3) are two ubiquitin-like conjugation systems that perform the elongation and closing of the autophagosome membrane. Autophagy receptors, i.e., p62/SQSTM1, identify ubiquitinated proteins or damaged organelles, bind to them, and attach them to LC3-II on the autophagosome membrane, enabling the sequestration of the cargo.[7] (Fig. 1). Subsequently, the autophagosome and lysosome join together to make an autolysosome. Lysosomal hydrolases break down the contents of the autolysosome, and they are then recycled back into the cytoplasm. These three proteins—the HOPS tethering complex, the GTPase Rab7, and the soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs)—are very critical to making this process feasible. A myriad of signaling path-



Fig. 1. Molecular mechanisms of autophagy.
mTORC1: The mechanistic target of rapamycin complex 1; ATGs: Autophagy-related genes; FIP200: Focal adhesion kinase family interacting protein of 200 kD; ULK1: UNC-51–like kinase 1; Vps: Vacuolar protein sorting; PI3Ks: Class 3 phosphoinositide 3-kinases; P62/SQSTM1: Protein Sequestosome 1; ILC3: Microtubule-associated protein 1A/1B-light chain 3; ILC3-II: ILC3- phosphatidylethanolamine conjugate.

Turk J Oncol 2025;40(3):242–251
doi: 10.5505/tjo.2025.4576

ways, including mTORC1, AMP-activated protein kinase (AMPK), and p53 pathways, react to cellular stress and energy levels to control autophagy. In addition, the PI3K/Akt pathway, which is an extrinsic signal-regulated kinase, as well as the cellular ERK and JNK pathways, which help cells stay alive and grow, are also involved in controlling autophagy.[8] The interplay between these pathways integrates several signals to precisely modulate the autophagic response and customize it according to intracellular requirements and extracellular factors.

Regulation of Autophagy by Oncogenes and Tumor Suppressors

Autophagy is regulated by a complex network of signaling pathways that respond to many cellular and environmental signals, including nutrition availability, energy levels, and stress signals. Oncogenes and tumor suppressor genes significantly influence numerous pathways involved in the initiation and advancement of cancer.[9] One example is the oncogene KRAS, which is commonly mutated in human malignancies. Studies have demonstrated that KRAS promotes autophagy by activating the RAF/MEK/ERK signaling cascade and blocking the mTOR pathway. This ultimately enables cancer cells to survive and thrive in stressful settings.[10] Conversely, the tumor suppressor gene PTEN, which is frequently inactivated or deleted in cancer, inhibits autophagy by enhancing the PI3K/AKT/mTOR signaling pathway, thereby resulting in improved cell proliferation and survival.[11] Understanding the molecular pathways through which oncogenes and tumor suppressors can control autophagy is essential for the creation of novel therapeutic strategies that target autophagy in cancer. By targeting the specific signaling pathways that regulate autophagy, and tailoring these interventions based on the unique genetic and molecular profiles of individual tumors, it may be possible to improve the precision and efficacy of autophagy-based therapies. This would allow for better management of cancer treatment and potentially reduce the risk of resistance and relapse.

Autophagy in Tumor Immunity

The relationship between autophagy and immunity is complicated. Depending on the stage of the disease, the type of cancer, and genetic factors, autophagy can either facilitate or inhibit the progression of the disease. This section explores the numerous functions of autophagy in tumor immunity, focusing particularly on its impact on immune evasion, tumor-associated inflammation, and TME.

Autophagy and Function of Immune Cells

Autophagy plays a vital role in the functioning and balance of different types of immune cells, such as T cells, B cells, NK cells, DCs, and macrophages. It achieves this by controlling their activation, differentiation, survival, and effectiveness.[12] Autophagy plays a pivotal role in maintaining T cell silence and preventing autoimmunity. It achieves this by eliminating damaged mitochondria and other cellular components, as well as regulating the expression of important molecules involved in T cell receptor (TCR) signaling and activation, such as CD3ζ and Linker for activation of T cells (LAT).[13] Furthermore, autophagy has been associated with the control of antigen presentation and cross-presentation by DCs and macrophages. It accomplishes this by aiding the processing and presentation of antigens on MHC class I and II molecules, as well as the release of pro-inflammatory cytokines like IL-1β and IL-18. These cytokines can enhance the activation of T cells and other components of the immune system. Furthermore, autophagy can regulate the cytotoxic activity of NK cells by controlling the expression of activating receptors like NKG2D and the release of cytotoxic granules such as perforin and granzymes. These granules are critical to the destruction of target cells.[14]

Autophagy and immune evasion

Tumor cells employ various strategies to evade the immune system, including reducing the expression of major histocompatibility complex (MHC) class I molecules, activating immunological checkpoint molecules, secretion of cytokines that weaken the immune system, and induction of regulatory T cells (Tregs).[15] Autophagy plays a role in several aspects of immune evasion, mostly by directly altering the process of presenting and recognizing antigens, as well as by affecting the function and fate of immune cells. Autophagy can promote the presentation of tumor antigens through MHC class I molecules, facilitating the identification and eradication of tumor cells by cytotoxic T lymphocytes (CTLs). Nevertheless, autophagy can inhibit the process of presenting antigens through MHC class II molecules, thus enhancing immune evasion and supporting the growth of tumors.[16] Further, autophagy can augment the production of immunological checkpoint molecules, like programmed cell death 1 (PD-1) and its ligand (PD-L1). These molecules restrict the activation and effectiveness of T cells, thereby contributing to the development of an immunosuppressive TME.[17] Autophagy can also regulate the activity and fate of immune cells within the TME. Autophagy, for

example, controls the survival, development, and immunosuppressive function of Tregs, which can weaken anti-tumor immune responses and facilitate tumor advancement.[18] Moreover, autophagy can facilitate the polarization of tumor-associated macrophages (TAMs) into an M2-like, anti-inflammatory phenotype, thereby promoting tumor development and metastasis. Conversely, autophagy can improve the cytotoxic efficacy of natural killer (NK) cells and CTLs, enabling them to eliminate cancer cells.[19]

Autophagy and Cancer Stem Cells

Cancer stem cells (CSCs) are a distinct group of cells inside a tumor that are able to renew themselves and differentiate into other cell types. These cells are thought to contribute to the initiation, growth, metastasis, and resistance to treatment of tumors.[20] Recent evidence indicates that autophagy plays an important role in the maintenance and functioning of CSCs, as well as their capability to adapt to stressful conditions such as hypoxia, food restriction, and chemotherapy.[21] Autophagy has been demonstrated to enhance the viability and stem cell-like characteristics of CSCs in many forms of cancer, such as glioblastoma, breast cancer, and colorectal cancer. This is accomplished through the regulation of key signaling pathways, including Wnt/β-catenin, Notch, and Hedgehog.[22] Additionally, inhibiting autophagy has been observed to impair the ability of CSCs to self-renew, develop tumors, and withstand chemotherapy in experimental models. This suggests that targeting autophagy may be a novel approach to eliminating CSCs and enhancing the effectiveness of cancer treatment.[23]

Autophagy and Tumor Microenvironment

Tumor Microenvironment (TME) comprises a complex and dynamic system of cellular and non-cellular constituents, including cancer cells, immune cells, fibroblasts, endothelial cells, extracellular matrix, and soluble molecules such as cytokines and growth factors. The TME plays a key role in cancer progression and therapeutic responses by influencing various biological processes, including proliferation, migration, angiogenesis, and immune evasion.[24] Recent studies have highlighted the importance of autophagy in the relationship between cancer cells and the TME, as well as in the ability of cancer cells to adapt to the fluctuating conditions within the TME, such as low oxygen levels, acidic pH, and a lack of nutrients.[25] For example, autophagy has been shown to assist in tumor angiogenesis by stimulating the release of pro-angiogenic substances like vascular endothelial growth factor (VEGF) and by maintaining the functionality of endothelial cells under stressful conditions.[26] Moreover, autophagy plays a role in regulating the interaction between cancer cells and immune cells in the TME, thereby influencing the immune response to malignancies. Autophagy has been found to improve the immunosuppressive capabilities of TAMs and myeloid-derived suppressor cells, as well as impair the cytotoxic function of NK cells and CD8+ T cells.[27] Metastasis, the spread of cancer cells from the primary tumor to distant organs, is the primary cause of cancer-related fatalities. Recent findings indicate that autophagy plays a crucial role in regulating metastasis by influencing several cellular processes, including epithelial-to-mesenchymal transition (EMT), cell migration, invasion, and resistance to anoikis.[28] Autophagy has been shown to promote EMT and invasion in breast cancer cells by degrading E-cadherin, an important regulator of cell-cell adhesion, and by activating focal adhesion kinase (FAK) signaling.[29] Furthermore, the suppression of autophagy has been observed to inhibit the ability of cancer cells to spread to other parts of the body in experimental models, highlighting the potential of targeting autophagy as a promising strategy for preventing and treating metastatic disease.[30]

Autophagy and Cancer-related Inflammation

Chronic inflammation plays a critical role in the initiation and progression of various cancers by facilitating DNA damage, genomic instability, angiogenesis, and immune evasion. Recent studies have highlighted the important role of autophagy in controlling inflammation and its impact on cancer. Autophagy has been found to regulate the activation of the inflammasome, a complex of several proteins involved in the innate immune response, thereby regulating the production and secretion of pro-inflammatory cytokines, especially interleukin-1β (IL-1β) and IL-18.[31] Other studies have demonstrated that autophagy affects the polarization and activity of TAMs, which have a prominent effect on defining the inflammatory TME and facilitating the progress of cancer.[32] Therefore, understanding the interplay between autophagy and inflammation may provide new insights into the mechanisms underlying cancer development and identify potential targets for therapeutic intervention. Tumor-associated inflammation is a determining factor in the development and progression

Turk J Oncol 2025;40(3):242–251
doi: 10.5505/tjo.2025.4576

of cancer. It can increase the growth, survival, blood vessel formation, invasion, and spread of tumor cells.[33] Autophagy plays a key role in the regulation of inflammation and the interaction between tumor cells and immune cells in the TME. Autophagy is able to regulate the activation of the inflammasome, a complex of multiple proteins that detect cellular stress and damage and trigger inflammatory responses. It impacts the production of pro-inflammatory cytokines, such as interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha (TNF)-α.[34] Besides, autophagy can impact the balance between pro-inflammatory and anti-inflammatory cytokines and modulate the polarization and functionality of immune cells inside the TME, including macrophages, dendritic cells (DCs), and T cells. Autophagy also controls the release of different growth factors, chemokines, and matrix metalloproteinases (MMPs) by both tumor cells and stromal cells. This process affects the recruitment, activation, and function of immune cells, as well as the restructuring of the extracellular matrix and the development of blood vessels. Consequently, autophagy contributes to the establishment of a tumor-supportive microenvironment.[35]

Autophagy and Therapy-induced Stress

Throughout the treatment process, cancer cells may encounter many stressors, including DNA damage, stress, and the buildup of unfolded proteins. These stressors might trigger the activation of autophagy as a mechanism for cell survival.[36] Chemotherapy and radiation are known to induce DNA double-strand breaks, which activate the DNA damage response (DDR). This leads to the expression of key ATGs, including ATG5 and Beclin 1 (BECN1), facilitating the autophagic process.[37] Likewise, specific treatments that inhibit cancer-causing signaling pathways, such as BRAF, EGFR, and HER2, can stimulate autophagy by causing cellular stress and triggering adaptive feedback mechanisms, which consequently, may lead to the development of drug resistance.[38] To enhance treatment efficacy and overcome resistance, targeting autophagy may be a promising strategy. By inducing cancer cell death or modifying the cellular stress response, autophagy modulation may sensitize cancer cells to therapy. However, careful timing is essential when manipulating autophagy, especially when combining autophagy inhibitors or activators with other treatments, to avoid unintended effects and maximize therapeutic benefits.[39]

Targeting Autophagy for Cancer Immunotherapy

Owing to the intricate and situation-specific involvement of autophagy in tumor immunity, targeting autophagy may be a promising approach for cancer treatment. Autophagy can be modulated using pharmacological drugs, genetic manipulation, or a combination of both. Here we focus on examining prospective therapeutic approaches to specifically target autophagy in cancer treatment, along with the associated challenges and future approaches in this field. Cancer immunotherapy, a therapeutic approach that utilizes the immune system's capabilities to combat cancer, has demonstrated promising outcomes, especially through the utilization of immune checkpoint inhibitors and T-cell therapy. However, many patients fail to respond or develop resistance to these treatments, highlighting the need for identifying new targets and strategies to improve their effectiveness. A growing area of research explores the relationship between autophagy and the immune system, as autophagy has been shown to impact several aspects of tumor immunity, including antigen presentation, T cell activation, and cytokine production.[35] The combination of autophagy and immunotherapy offers a promising strategy to improve immune responses against tumors and overcome resistance to current therapies.

Recently advances in the development of small chemicals and biologic elements can control autophagy in cancer cells. These advancements involve strategies such as inhibiting autophagosome formation, obstructing the availability of autophagic energy sources, or targeting the signaling pathways that regulate autophagy. Several medicines, including HCQ and its derivatives, have been tested in clinical studies in combination with chemotherapy, targeted treatment, or immunotherapy. These trials have demonstrated promising results in terms of the rate of response and progression-free survival.[40] However, the effectiveness of autophagy-targeting agents in treating diseases may be insufficient due to various factors. These factors consist of the diverse expression and function of ATGs in different types of cancer, the activation of alternative survival pathways, and the potential unwanted effects on healthy tissues.[41] To address these issues, researchers are focusing on identifying more specific and potent autophagy inhibitors and developing biomarkers and predictive tools that can help select the right patients for treatment and better manage therapeutic strategies. Moreover, combining autophagy modulation with other treatment strategies, such as metabolic reprogramming, immune checkpoint inhibition, or se-

nescence induction, holds the potential for synergistic anti-tumor effects. This combination approach might result in enhanced clinical outcomes by overcoming resistance mechanisms and boosting the immune response to tumors.[42] Several preclinical studies have demonstrated that combining autophagy targeting with cancer immunotherapy, e.g., immune checkpoint blockage, adoptive T cell transfer, or cancer vaccines, might improve the immune response against tumors and improve therapeutic effectiveness.[14] Blocking autophagy using HCQ or removing ATGs like Atg5 or Atg7 has been demonstrated to enhance the effectiveness of anti-PD-1 or anti-CTLA-4 therapy in various mouse models of cancer. This combination therapy works by promoting T-cell activation, increasing T-cell infiltration into the tumor, and reducing the expression of immunosuppressive factors in TME.[43]

Pharmacological Modulation of Autophagy

A variety of pharmaceutical compounds have been developed to regulate autophagy by either limiting the creation of autophagosomes, blocking the fusion of autophagosomes with lysosomes, or interfering with the breakdown of autophagic cargo. Certain compounds, such as chloroquine (CQ) and hydroxychloroquine (HCQ), have already received approval for treating other diseases. CQ is utilized as an antimalarial medicine, whereas HCQ is an anti-inflammatory drug. These agents have been repurposed for cancer therapy.[20] CQ and HCQ function as lysosomotropic drugs by accumulating in lysosomes and raising their pH levels. This disrupts the activity of lysosomal hydrolases and prohibits the breakdown of autophagic cargo.[44] These medications have been examined alongside different chemotherapy agents, targeted treatments, and immunotherapies in both preclinical and clinical investigations. The findings have been promising, indicating improved effectiveness against tumors and the ability to overcome therapeutic resistance.[39] However, the most effective dose, schedule, and indicators for selecting patients, along with the possible adverse effects and toxicities associated with prolonged autophagy suppression, remain unclear.[38]

Another pharmaceutical compound targeting autophagy is 3-methyladenine (3-MA), which inhibits the class III PI3K complex and blocks the development of autophagosomes. Bafilomycin A1 is a substance that inhibits the activity of vacuolar-type H+-ATPase (V-ATPase), thereby preventing the acidification of lysosomes and the breakdown of the autophagic cargo.[45] These agents have primarily been utilized as research instruments for investigating the involvement of autophagy in cancer and other diseases. Nonetheless, their therapeutic potential and safety profiles warrant further investigation. Furthermore, other compounds that promote autophagy have been explored for their potential in cancer treatment, either as standalone therapies or in combination with other therapeutic approaches. Rapamycin and its analogs, known as rapalogs, are agents that hinder mTORC1 and stimulate autophagy.[46] Metformin, a medication used to treat diabetes mellitus, stimulates AMPK and suppresses mTORC1, resulting in the activation of autophagy and the manifestation of anti-proliferative properties. Furthermore, it exhibits anti-inflammatory properties, specifically targeting tumor cells and cells of the immune system. Additional autophagy stimulants, including spermidine, resveratrol, and curcumin, have demonstrated anticancer and immunomodulatory properties in preliminary laboratory investigations. However, their effectiveness and safety in clinical settings require further evaluation.[47]

Genetic Manipulation of Autophagy

Genetic manipulation of autophagy, achieved by either the overexpression or destruction of specific autophagy-related genes (ATGs), has been served as a method to investigate the function of autophagy in tumor immunity and therapy and develop new therapeutic methods. For instance, overexpressing Beclin 1 or disrupting Bcl-2, a protein that inhibits Beclin 1 and autophagy, has been shown to enhance autophagy and increase the sensitivity of tumor cells to chemotherapy and radiotherapy in preclinical models. On the other hand, the elimination of pivotal ATGs, such as Atg5, Atg7, or Atg12, has been utilized to impair autophagy and investigate its impact on tumor development, metastasis, and immune response in various cancer models.[48] Research has shown that inhibiting the genetic process of autophagy can decrease tumor growth and improve the effectiveness of immunotherapy. This provides strong support for considering the targeting of autophagy in combination with immune checkpoint inhibitors or adoptive T-cell treatment.[43] The development of gene therapy techniques, such as the delivery of ATGs or small interfering RNAs (siRNAs) targeting ATGs via viral or non-viral vectors, holds significant promise for modulating autophagy in tumor cells or immune cells, thereby enhancing the effectiveness of cancer treatments.[33] Nevertheless, it is crucial to further optimize and validate these methods in preclinical and clinical trials to ensure their efficacy, precision, and safety.

Turk J Oncol 2025;40(3):242–251
doi: 10.5505/tjo.2025.4576

Challenges and Future Directions

Although there is increasing evidence suggesting the involvement of autophagy in immunity and tumor therapy, numerous challenges and unresolved challenges persist. A more comprehensive understanding of the complex and context-dependent nature of autophagy is essential. This process can either promote tumor growth or inhibit it, depending on the illness stage, cancer type, and unique genetic and environmental factors. Furthermore, there is a need for more precise targeting of this mechanism in the context of cancer treatment. Additionally, for autophagy-targeting strategies to be successfully applied in clinical settings, there must be progress in developing more precise and effective autophagy modulators, along with the identification of reliable biomarkers for patient selection and treatment response monitoring. Finally, it is necessary to investigate the interaction between autophagy and many cellular processes, including apoptosis, senescence, and metabolism. Furthermore, understanding how autophagy communicates with the immune system is key to elucidating the mechanisms that underlie the differing effects of autophagy modulation on tumors. Immune cells are being utilized to develop more efficient and less harmful therapeutic approaches.

Understanding the Complications of Autophagy in Cancer

Autophagy is a highly dynamic and context-dependent process that plays a significant role in cancer. Studies have demonstrated that the presence of specific elements, such as the type of cancer, stage, and genetic background, can result in the manifestation of anti-tumorogenic and anti-tumor properties. As a result, a comprehensive understanding of how autophagy impacts cancer progression is essential for developing effective treatment strategies. Researchers are currently focusing on creating advanced experimental models and technologies, such as genetically engineered mouse models, organoids, and single-cell sequencing, to more accurately reflect the complex nature of human tumors and their surrounding TME. To make sense of the vast amounts of data generated by these studies, systems biology approaches, including computational modeling and network analysis, are being used to integrate and analyze the information. The goal is to identify critical regulatory nodes and pathways related to autophagy and cancer.[18]

Development of Autophagy Modulators

The identification and validation of autophagy modulators with greater specificity and potency are vital for successfully translating autophagy-targeting strategies into clinical practice. So far, several small molecules, such as CQ and HCQ, have been used to inhibit autophagy in preclinical and clinical studies. Nevertheless, these agents have limitations, such as poor selectivity, off-target effects, and the development of resistance. It is crucial to identify and confirm autophagy modulators that have more specificity and potency in order to effectively implement autophagy-targeting approaches in a clinical setting. To date, numerous small compounds, such as CQ and HCQ, have been applied to suppress autophagy in preclinical and clinical investigations. However, these agents have limitations such as inadequate selectivity, off-target effects, and the emergence of resistance.[19]

Identifying Biomarkers for Patient Selection and Monitoring

A major challenge in autophagy-targeting therapy is identifying patients who are most likely to benefit from these treatments, as well as monitoring their response and potential adverse effects. To address this issue, researchers are actively exploring reliable and non-invasive biomarkers, such as circulating tumor cells, cell-free DNA, or extracellular vesicles. These biomarkers have the potential to accurately predict the response to autophagy modulators and assist in the selection of patients for clinical trials and personalized medicine.[33] Moreover, the progress in the field of imaging methods and tools, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), which are able to observe and measure autophagy in living organisms, will be crucial to evaluating the effectiveness of treatments and improving the dosage and timing in clinical research.[34]

Interplay between Autophagy and Other Cellular Processes

Autophagy contributes to other biological processes, including apoptosis, aging, and metabolism. A deeper understanding of these processes and their influence on the dissemination of cancer and the efficacy of treatment is crucial for the advancement of more potent therapeutic approaches. One example of this is the relationship between apoptosis and autophagy, which are two primary processes involved in cell death. This interaction is particularly prominent in the context of cancer, as numerous anticancer treatments depend on initiation of apoptosis to eradicate tumor cells. Recent research demonstrates

that autophagy can either promote or inhibit apoptosis. Concomitantly targeting both processes may enhance the effectiveness of therapy and overcome resistance to treatment.[49]

Autophagy Modulation as an Adjuvant Therapy

Owing to the intricate and diverse nature of autophagy's involvement in cancer, it is probable that solely focusing on autophagy may not be sufficient to produce substantial therapeutic outcomes, especially in advanced and aggressive cancers. However, regulating autophagy could serve as an adjunctive strategy to improve the efficacy of existing treatments and overcome resistance to therapies, including chemotherapy, targeted therapy, and immunotherapy.[38] Numerous preclinical and clinical studies have shown that inhibiting autophagy can increase the susceptibility of cancer cells to various anti-cancer drugs, including temozolomide, cisplatin, and BRAF inhibitors. This is achieved by promoting cell death, suppressing survival pathways, and preventing the development of resistance mechanisms.[39] Additionally, activating autophagy may offer a protective effect for healthy tissues against the damaging side effects of radiation and chemotherapy, potentially improving the therapeutic index and increasing patient tolerance to these treatments.[50]

CONCLUSION

Autophagy plays a dual role in cancer, influencing tumor progression and therapy outcomes based on specific cellular and microenvironmental conditions. Its ability to aid cellular survival, stress adaptation, and immune modulation makes it a critical therapeutic target. Advances in molecular and pharmacological methods offer promising strategies to enhance the efficacy of cancer treatments by regulating autophagy, including sensitizing cancer cells to therapies and reducing treatment resistance. However, challenges remain in developing precise autophagy modulators, identifying predictive biomarkers, and optimizing combination therapies. A deeper understanding of autophagy's role in tumor biology, including its impact on the tumor microenvironment, metastasis, and immunity, is crucial. Global efforts are expected to drive the emergence of innovative autophagy-based therapeutic strategies, bridging the gap between laboratory discoveries and clinical applications, and improving cancer patient outcomes.

Conflict of Interest Statement: The authors have no conflicts of interest to declare.

Funding: This research received no specific grant, funding, equipment or supplies from any funding agency in the public, commercial, or not-for-profit sectors.

Use of AI for Writing Assistance: No AI technologies utilized.

Author Contributions: Concept – M.K., N.R.; Supervision – M.K., M.E., S.A.S.A.K., H.N.; Funding – N.R.; Materials – N.R.; Data collection and/or processing – N.R., S.A.S.A.K., M.E., H.N.; Data analysis and/or interpretation – N.R.; Literature search – N.R.; Writing – M.K., S.A.S.A.K., M.E., H.N.; Critical review – N.R.

Peer-review: Externally peer-reviewed.

REFERENCES

1. de la Ballina LR, Munson MJ, Simonsen A. Lipids and lipid-binding proteins in selective autophagy. J Mol Biol 2020;432(1):135–59.
2. Zhang T, Yu J, Cheng S, Zhang Y, Zhou C, Qin J, et al. Research progress on the anticancer molecular mechanism of targets regulating cell autophagy. Pharmacology 2023;108(3):224–37.
3. Burgos-Molina AM, Santana TT, Redondo M, Romero MJB. The crucial role of inflammation and the immune system in colorectal cancer carcinogenesis: A comprehensive perspective. Int J Mol Sci 2024;25(11):6188.
4. Chen S, Wang C, Yeo S, Liang C, Okamoto T, Sun S, et al. Distinct roles of autophagy-dependent and -independent functions of FIP200 revealed by generation and analysis of a mutant knock-in mouse model. Genes Dev 2016;30(7):856–69.
5. Shen JZ, Wu G, Guo S. Amino acids in autophagy: Regulation and function. Adv Exp Med Biol 2021;1332:51–66.
6. Zhong Y, Morris DH, Jin L, Patel MS, Karunakaran SK, Fu YJ, et al. Nrbf2 protein suppresses autophagy by modulating Atg14L protein-containing Beclin 1-Vps34 complex architecture and reducing intracellular phosphatidylinositol-3 phosphate levels. J Biol Chem 2014;289(38):26021–37.
7. Pantoom S, Konstandtinidis G, Voss S, Han H, Hofnagel O, Li Z, et al. RAB33B recruits the ATG16L1 complex to the phagophore via a noncanonical RAB binding protein. Autophagy 2021;17(9):2290–304.
8. Kim SH, Kim H. Astaxanthin modulation of signaling pathways that regulate autophagy. Mar Drugs 2019;17(10):546.
9. White E. The role for autophagy in cancer. J Clin Invest 2015;125(1):42–6.

Turk J Oncol 2025;40(3):242–251
doi: 10.5505/tjo.2025.4576

10. Guo JY, Karsli-Uzunbas G, Mathew R, Aisner SC, Kamphorst JJ, Strohecker AM, et al. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev 2013;27(13):1447–61.
11. Yu M, Gou W, Zhao S, Xiao L, Mao X, Xing Y, et al. Beclin 1 expression is an independent prognostic factor for gastric carcinomas. Tumour Biol 2013;34(2):1071–83.
12. Deretic V, Levine B. Autophagy, immunity, and microbial adaptations. Cell Host Microbe 2009;5(6):527–49.
13. Pua HH, Dzhagalov I, Chuck M, Mizushima N, He YW. A critical role for the autophagy gene Atg5 in T cell survival and proliferation. J Exp Med 2007;204(1):25–31.
14. O'Sullivan TE, Geary CD, Weizman OE, Geiger TL, Rapp M, Dorn GW 2nd. Atg5 is essential for the development and survival of innate lymphocytes. Cell Rep 2016;15(9):1910–9.
15. Takeuchi M, Miyoshi H, Ohshima K. Tumor microenvironment of adult T-cell leukemia/lymphoma. J Clin Exp Hematop 2021;61(4):202–9.
16. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011;334(6062):1573–7.
17. Baginska J, Viry E, Berchem G, Poli A, Noman MZ, van Moer K, et al. Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia. Proc Natl Acad Sci U S A 2013;110(43):17450–5.
18. Vidal M, Cusick ME, Barabási AL. Interactome networks and human disease. Cell 2011;144(6):986–98.
19. Pasquier B. Autophagy inhibitors. Cell Mol Life Sci 2016;73(5):985–1001.
20. Batlle E, Clevers H. Cancer stem cells revisited. Nat Med 2017;23(10):1124–34.
21. Wang X, Lee J, Xie C. Autophagy regulation on cancer stem cell maintenance, metastasis, and therapy resistance. Cancers (Basel) 2022;14(2):381.
22. Gong C, Bauvy C, Tonelli G, Yue W, Deloménie C, Nicolas V, et al. Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like/progenitor cells. Oncogene 2013;32(18):2261–72.
23. Sharif T, Martell E, Dai C, Kennedy BE, Murphy P, Clements DR, et al. Autophagic homeostasis is required for the pluripotency of cancer stem cells. Autophagy 2017;13(2):264–84.
24. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013;19(11):1423–37.
25. Maes H, Kuchnio A, Peric A, Moens S, Nys K, De Bock K, et al. Tumor vessel normalization by chloroquine independent of autophagy. Cancer Cell 2014;26(2):190–206.
26. Huang H, Langenkamp E, Georganaki M, Loskog A, Fuchs PF, Dieterich LC, et al. VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation. Faseb J 2015;29(1):227–38.
27. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 2017;14(7):399–416.
28. Zhang M, Hong X, Ma N, Wei Z, Ci X, Zhang S. The promoting effect and mechanism of Nrf2 on cell metastasis in cervical cancer. J Transl Med 2023;21(1):433.
29. Kong DB, Chen F, Sima N. Focal adhesion kinases crucially regulate TGFβ-induced migration and invasion of bladder cancer cells via Src kinase and E-cadherin. Onco Targets Ther 2017;10:1783–92.
30. Cararo Lopes E, Sawant A, Moore D, Ke H, Shi F, Laddha S, et al. Integrated metabolic and genetic analysis reveals distinct features of human differentiated thyroid cancer. Clin Transl Med 2023;13(6):e1298.
31. Sun Q, Fan J, Billiar TR, Scott MJ. Inflammasome and autophagy regulation – a two-way street. Mol Med 2017;23:188–95.
32. Kuo WT, Chang JM, Chen CC, Tsao N, Chang CP. Autophagy drives plasticity and functional polarization of tumor-associated macrophages. IUBMB Life 2022;74(2):157–69.
33. Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema, et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy 2018;14(8):1435–55.
34. Kumar M, Salem K, Michel C, Jeffery JJ, Yan Y, Fowler AM. (18)F-fluoroestradiol PET imaging of activating estrogen receptor-α mutations in breast cancer. J Nucl Med 2019;60(9):1247–52.
35. Galluzzi L, Buqué A, Kepp O, Zitgovel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol 2017;17(2):97–111.
36. Gewirtz DA. The four faces of autophagy: implications for cancer therapy. Cancer Res 2014;74(3):647–51.
37. Chen L, Ye HL, Zhang G, Yao WM, Chen XZ, Zhang FC, et al. Autophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatoma Hep3B cells. PLoS One 2014;9(1):e85771.
38. Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer 2017;17(9):528–42.
39. Amaravadi R, Kimmelman AC, White E. Recent insights into the function of autophagy in cancer. Genes Dev 2016;30(17):1913–30.
40. Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, et al. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and con-

current and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 2014;10(8):1359–68.
41. Rebecca VW, Amaravadi RK. Emerging strategies to effectively target autophagy in cancer. Oncogene 2016;35(1):1–11.
42. Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, et al. Autophagy in malignant transformation and cancer progression. Embo J 2015;34(7):856–80.
43. Starobinets H, Ye J, Broz M, Barry K, Goldsmith J, Marsh T, et al. Antitumor adaptive immunity remains intact following inhibition of autophagy and antimalarial treatment. J Clin Invest 2016;126(12):4417–29.
44. White E, Mehnert JM, Chan CS. Autophagy, metabolism, and cancer. Clin Cancer Res 2015;21(22):5037–46.
45. Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R, Tashiro Y. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct 1998;23(1):33–42.
46. Kim J, Kundu, M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 2011;13(2):132–41.
47. Ni YQ, Liu YS. New insights into the roles and mechanisms of spermidine in aging and age-related diseases. Aging Dis 2021;12(8):1948–63.
48. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 2006;10(1):51–64.
49. Mariño G, Niso-Santano M, Baehrecke EH, Kroemer G. Self-consumption: the interplay of autophagy and apoptosis. Nat Rev Mol Cell Biol 2014;15(2):81–94.
50. Saleh T, Tyutyunyk-Massey L, Gewirtz DA. Tumor cell escape from therapy-induced senescence as a model of disease recurrence after dormancy. Cancer Res 2019;79(6):1044–6.